ArticleEuropean journal of immunology2014
Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.
Article in European journal of immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.Retrovirology · 2016Trial
- Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine.Nature communications · 2025Article
- Discrimination of primary and chronic cytomegalovirus infection based on humoral immune profiles in pregnancy.The Journal of clinical investigation · 2024Article
- Development of systemic and mucosal immune responses against gut microbiota in early life and implications for the onset of allergies.Frontiers in allergy · 2024Review
- Distinct effector functions mediated by Fc regions of bovine IgG subclasses and their interaction with Fc gamma receptors.Frontiers in immunology · 2023Article
- Selective transfer of maternal antibodies in preterm and fullterm children.Scientific reports · 2022Article
- Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge.Science immunology · 2022Article
- HIV-gp140-Specific Antibodies Generated From Indian Long-Term Non-Progressors Mediate Potent ADCC Activity and Effectively Lyse Reactivated HIV Reservoir.Frontiers in immunology · 2022Article
- Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection.Journal of virology · 2021Article
- Article
- Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies.PLoS pathogens · 2020Article
- IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody.PLoS pathogens · 2019Article
- Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1.Current opinion in HIV and AIDS · 2019Review
- The Antibodiome-Mapping the Humoral Immune Response to HIV.Current HIV/AIDS reports · 2019Review
- TRIM21-From Intracellular Immunity to Therapy.Frontiers in immunology · 2019Review
- An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.Frontiers in immunology · 2019Review
- Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function.Frontiers in immunology · 2019Review
- IgG3 regulates tissue-like memory B cells in HIV-infected individuals.Nature immunology · 2018Article
- HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.PLoS pathogens · 2018Article
- Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors.AIDS (London, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Fc-related antibody activities, such as antibody-dependent cellular cytotoxicity (ADCC), or more broadly, antibody-mediated cellular viral inhibition (ADCVI), play a role in curbing early SIV viral replication, are enriched in human long-term infected nonprogressors, and could potentially contribute to protection from infection. However, little is known about the mechanism by which such humoral immune responses are naturally induced following infection. Here, we focused on the early evolution of the functional antibody response, largely driven by the Fc portion of the antibody, in the context of the evolving binding and neutralizing antibody response, which is driven mainly by the antibody-binding fragment (Fab). We show that ADCVI/ADCC-inducing responses in humans are rapidly generated following acute HIV-1 infection, peak at approximately 6 months postinfection, but decay rapidly in the setting of persistent immune activation, as Fab-related activities persistently increase. Moreover, the loss of Fc activity occurred in synchrony with a loss of HIV-specific IgG3 responses. Our data strongly suggest that Fc- and Fab-related antibody functions are modulated in a distinct manner following acute HIV infection. Vaccination strategies intended to optimally induce both sets of antiviral antibody activities may, therefore, require a fine tuning of the inflammatory response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.